Pharma Vision 2000 AG has taken a 0.5% stake in Hoechst AG for $134.5million, and will lobby for a spin-off of Hoechst Marion Roussel. PV2000 director Peter Sjostrand said that Hoechst can realize the value of HMR by spinning it off, which he expects to happen in the next two years.
Meantime, PV2000 has invested 41 million Swiss francs ($27.7 million) in Tularik of the USA for a 10% stake. It would like to see the biotechnology firm listed on the NASDAQ this year. Tularik is capitalized at around $300 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze